Could Cybin Be a Millionaire-Maker Stock?
For millennia, people have loved many varieties of mushrooms for their delicious utility in culinary pursuits. But in modern times, the use of psychedelic mushrooms has largely been relegated to the fringes. Soon, however, the remarkable properties of those fungi could place them at the center of a new evolution in mental health therapies -- or so hopes the clinical-stage Canadian pharmaceutical company Cybin (OTC: CLXP.F).
Cybin's focus is on psychedelic medicines that could address depression, anxiety, addiction, and other tough-to-treat mental illnesses. While the company is still relatively early in the R&D process, there's a lot to like about its efforts so far.
And for investors on the hunt for potential millionaire-maker stocks, it's definitely worth a look: It wouldn't be surprising at all if, over the course of the next decade, Cybin's valuation increases tenfold.
Source Fool.com